Samsung Peptide Tender Offer Secures 97.98% of Shares
PolyPeptide Group AG said its tender offer for Samsung Peptide secured 97.98% of shares.
Related stories
Egetis Board Recommends ANI Pharmaceuticals’ Cash Offer
Egetis Therapeutics’ board recommends ANI Pharmaceuticals’ cash offer.
M impact | MNA | Nov 05, 2026, 06:19 AM UTC
Commerzbank Says UniCredit Deal Could Create Value
Commerzbank’s CEO said the lender was convinced a deal with UniCredit could create value. The statement came as Commerzbank reported a 45% increase in third-quarter profit.
M impact | MNA | Nov 05, 2026, 06:18 AM UTC
Egetis board unanimously recommends ANI cash offer at SEK 11.25 per share
Egetis’ board unanimously recommends ANI’s cash offer of SEK 11.25 per share, valuing the offer at approximately SEK 5,304M; holders of approximately 42.2% of outstanding shares ag
M impact | MNA | Nov 05, 2026, 06:16 AM UTC
Samsung Biologics Reaches a Definitive Stake in PolyPeptide
Samsung Biologics has reached a definitive stake in PolyPeptide.
M impact | MNA | Nov 05, 2026, 06:15 AM UTC
China blocks billion-dollar ABB robotics deal
Reuters reports that China is blocking a billion-dollar deal involving ABB robotics.
M impact | MNA | Nov 05, 2026, 06:15 AM UTC
Dong-A Pharmaceutical Unit to Sell D&T Holding Stake for KRW 39.87 Billion
A Dong-A Pharmaceutical unit will sell its stake in D&T Holding for KRW 39.87 billion.
M impact | MNA | Nov 05, 2026, 06:11 AM UTC